Mara Goldstein
Stock Analyst at Mizuho
(2.61)
# 2,299
Out of 5,090 analysts
69
Total ratings
48.08%
Success rate
16.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $11.95 | +151.05% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.20 | +354.55% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $10.36 | -22.78% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $25.45 | +65.03% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $17.30 | +189.02% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $20.32 | +121.46% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $102.52 | -24.89% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $3.27 | +114.07% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.08 | +640.74% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $56.90 | +58.17% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $8.81 | -60.27% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.79 | +20,011.73% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $6.40 | +212.50% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $99.72 | +30.37% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $3.95 | -49.37% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.55 | +674.19% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $65.67 | -69.54% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.92 | +506.06% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.45 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.98 | +134.11% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $11.95
Upside: +151.05%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.20
Upside: +354.55%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $10.36
Upside: -22.78%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $25.45
Upside: +65.03%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $17.30
Upside: +189.02%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $20.32
Upside: +121.46%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $102.52
Upside: -24.89%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $3.27
Upside: +114.07%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.08
Upside: +640.74%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $56.90
Upside: +58.17%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $8.81
Upside: -60.27%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.79
Upside: +20,011.73%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $6.40
Upside: +212.50%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $99.72
Upside: +30.37%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $3.95
Upside: -49.37%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.55
Upside: +674.19%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $65.67
Upside: -69.54%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.92
Upside: +506.06%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $29.45
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.98
Upside: +134.11%